Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Blind, and Positive Control Design to Evaluate the Immunization Efficacy of 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 18-26 Years

Next Previous
Trial Profile

A Randomized, Blind, and Positive Control Design to Evaluate the Immunization Efficacy of 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 18-26 Years

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Human papillomavirus vaccine (Primary) ; V 503
  • Indications Human papillomavirus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors National Vaccine & Serum Institute

Most Recent Events

  • 05 May 2022 Status changed from active, no longer recruiting to completed.
  • 13 Feb 2022 Planned End Date changed from 22 Dec 2021 to 22 Mar 2022.
  • 13 Feb 2022 Planned primary completion date changed from 22 Dec 2021 to 22 Mar 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top